New targets and approaches in osteosarcoma

Jonathan Gill, Manpreet K. Ahluwalia, David S. Geller, Richard Gorlick

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy. Only 1/3 of patients with metastases detectable at presentation will be cured. These survival trends have stagnated over the past 20 years using conventional chemotherapy. New agents need to be rationally investigated to strive for improvement in the survival of patients diagnosed with osteosarcoma. This manuscript will review the rationale for conventional chemotherapy used in the treatment of osteosarcoma, as well as agents in varying stages of development that may have promise for treatment in the future.

Original languageEnglish (US)
Pages (from-to)89-99
Number of pages11
JournalPharmacology and Therapeutics
Volume137
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Osteosarcoma
Drug Therapy
Survival
Neoplasm Metastasis
Bone and Bones
Therapeutics
Neoplasms

Keywords

  • Chemotherapy
  • Novel agents
  • Osteosarcoma
  • Review

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New targets and approaches in osteosarcoma. / Gill, Jonathan; Ahluwalia, Manpreet K.; Geller, David S.; Gorlick, Richard.

In: Pharmacology and Therapeutics, Vol. 137, No. 1, 01.2013, p. 89-99.

Research output: Contribution to journalArticle

Gill, Jonathan ; Ahluwalia, Manpreet K. ; Geller, David S. ; Gorlick, Richard. / New targets and approaches in osteosarcoma. In: Pharmacology and Therapeutics. 2013 ; Vol. 137, No. 1. pp. 89-99.
@article{5c99ea0175c14440b4cbe752a1cea322,
title = "New targets and approaches in osteosarcoma",
abstract = "Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy. Only 1/3 of patients with metastases detectable at presentation will be cured. These survival trends have stagnated over the past 20 years using conventional chemotherapy. New agents need to be rationally investigated to strive for improvement in the survival of patients diagnosed with osteosarcoma. This manuscript will review the rationale for conventional chemotherapy used in the treatment of osteosarcoma, as well as agents in varying stages of development that may have promise for treatment in the future.",
keywords = "Chemotherapy, Novel agents, Osteosarcoma, Review",
author = "Jonathan Gill and Ahluwalia, {Manpreet K.} and Geller, {David S.} and Richard Gorlick",
year = "2013",
month = "1",
doi = "10.1016/j.pharmthera.2012.09.003",
language = "English (US)",
volume = "137",
pages = "89--99",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - New targets and approaches in osteosarcoma

AU - Gill, Jonathan

AU - Ahluwalia, Manpreet K.

AU - Geller, David S.

AU - Gorlick, Richard

PY - 2013/1

Y1 - 2013/1

N2 - Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy. Only 1/3 of patients with metastases detectable at presentation will be cured. These survival trends have stagnated over the past 20 years using conventional chemotherapy. New agents need to be rationally investigated to strive for improvement in the survival of patients diagnosed with osteosarcoma. This manuscript will review the rationale for conventional chemotherapy used in the treatment of osteosarcoma, as well as agents in varying stages of development that may have promise for treatment in the future.

AB - Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy. Only 1/3 of patients with metastases detectable at presentation will be cured. These survival trends have stagnated over the past 20 years using conventional chemotherapy. New agents need to be rationally investigated to strive for improvement in the survival of patients diagnosed with osteosarcoma. This manuscript will review the rationale for conventional chemotherapy used in the treatment of osteosarcoma, as well as agents in varying stages of development that may have promise for treatment in the future.

KW - Chemotherapy

KW - Novel agents

KW - Osteosarcoma

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84872307406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872307406&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2012.09.003

DO - 10.1016/j.pharmthera.2012.09.003

M3 - Article

C2 - 22983152

AN - SCOPUS:84872307406

VL - 137

SP - 89

EP - 99

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -